Technology

Artificial Intelligence Big Data Cloud Computing Cyber Security Data Management Electronics Enterprise & Network Technology Financial Technology Hardware Mobile & Wireless Nanotechnology Semiconductor Software Telecommunications
News Release Digital Asset Direct

PathAI Announces Expansion of BioPharma Lab to Provide End-to-End Central Pathology and Histology Services

PathAI

PathAI, a global leader in AI-powered pathology, today announced the expansion of its BioPharma Laboratory Services. Capitalizing on the 30-year history of delivering high quality pathology services in the PathAI Diagnostics clinical laboratory (formerly known as Poplar Healthcare), PathAI offers biopharma partners a comprehensive, GCP/GCLP compliant histology and digital pathology lab to support prospective clinical trials across oncology, liver, and gastrointestinal indications. The lab offers pharmaceutical companies access to unparalleled histological laboratory services and comprehensive operational support, encompassing the full end-to-end tissue processing from kitting and logistics management, tissue processing and staining across H&E, IHC, and special stains; local and remote pathology tapping into PathAI’s network of >500 US board-certified pathologists; and AI-driven analysis from PathAI’s menu of algorithms and clinical trial software. This integrated approach enables the streamlined, proficient, and regulatory-compliant implementation of controlled clinical trials, all within a single facility. PathAI’s BioPharma Lab has a unique combination of capabilities to enable clinical trials where pathology-based endpoints, biomarker classification, and/or superior histology quality are critical to the success of their pharma partners. Over the last two years, the company has already supported Phase 2 clinical trials in NASH, IBD, and breast cancer, as well as oncology neoadjuvant trials. Based on successfully meeting key milestones on quality and turnaround times, PathAI is expanding and scaling its services to new trial indications and partners. The lab adheres to all relevant quality, regulatory, and compliance standards including CAP/CLIA and GCP/GCLP. In addition to full laboratory support for clinical trials, PathAI’s BioPharma Lab supports trials through its AI products and expertise with AI-powered endpoint assessment and patient enrollment. “We don’t just create algorithms, we stay in lock step with our pharma partners to ensure our AI products are integrated into trials appropriately, based on regulatory criteria, to enhance trial quality and efficiency,” said Andy Beck, MD, PhD, CEO of PathAI. The BioPharma Lab’s expertise helps reduce the impact of many challenges associated with clinical trials, including unreliable turnaround times, variable histology, stain or scan/digitization quality, and challenging assessment of histological endpoints. In addition, the lab allows pharma partners the ability to use AI without a heavy lift to implement. The lab offers most major types of instrumentation, with flexible workflows across different scanners, stains, and biopsy types, which improves the quality of clinical trials. Importantly, the services include access to PathAI’s extensive network of over 500 US Board Certified pathologists to perform high quality reading with rapid turnaround time in a cost-effective manner. “During my time running translational sciences in a Top 10 pharma company, I witnessed a strong need for high quality, scalable, and flexible pathology services that can further be combined with the state-of-the-art technology in digital pathology and AI,” said Mike Montalto, PhD, Chief Scientific Officer, of PathAI. “We took a pharma-first approach when establishing this lab and its offerings.” The BioPharma Lab will physically expand in 2024 to allow an increase in sample throughput to accommodate larger scale global phase 3 studies, as well as additional equipment to support a wider range of clinical studies. Learn more about how PathAI’s BioPharma Lab can power your next clinical trial by contacting BD@pathai.com or visiting https://www.pathai.com/clinical-trial-services/. PathAI will be at several upcoming conferences with representatives available to speak about the lab’s capabilities, including ESMO, SCOPE Europe (booth #4), and SCOPE Orlando (booth #206). About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

September 19, 2023 10:00 AM Eastern Daylight Time

Velocity Global Appoints Jeff Woolard as Chief Financial Officer

Velocity Global

Velocity Global, the world’s expert on work, today announced the appointment of Jeff Woolard as Chief Financial Officer. Effective immediately, Jeff will drive the overall financial execution, strategic planning, and create a financial growth strategy for the company. “Jeff’s financial, strategic, and operational experience will make an immeasurable impact that will help Velocity Global take new heights. His proven track record will be critical in helping us achieve strategic initiatives aimed at providing our customers with the best possible experience,” said Frank Calderoni, CEO at Velocity Global. “Jeff’s experience as a CFO provides a unique perspective in that he understands better than anyone the challenges associated with scaling a global team. His insights will allow us to build a more scalable and strategic offering that enhances the customer journey and grows our footprint across the industry.” With nearly 3 decades of experience in both finance and technology, Jeff will provide in-depth experience in driving strategy to execution, growth, and profitability. He most recently served as Chief Financial Officer at Solidigm, providing him with not only the experience needed to grow a company at scale, but also a lens into the challenges faced by global CFOs as they grow their teams in efficient and compliant ways. Jeff also spent more than 25 years in various leadership positions with Intel, including its manufacturing and technology organization, Foundry and Intel Capital, and has led and overseen large M&A transactions, including Intel's acquisition of Mobileye. “I am excited to be joining Velocity Global at a critical time in its trajectory,” says Jeff Woolard, Chief Financial Officer of Velocity Global. “As a CFO, I can attest to the criticality of the type of service the company provides and what a difference it can make in scaling a company in a compliant way. I’m looking forward to working with the team at Velocity Global as we grow the business and help leaders build their teams in ways they never thought possible.” Jeff’s announcement comes shortly after the appointments of Chief Transformation Officer Susan McDonough and Chief Customer Success Officer Frank Lucier, who both joined the company last month. Chief Revenue Officer Ann-Christel Graham and Chief People Officer Linda Lee were both brought on earlier this year by CEO Frank Calderoni, who took on the role in April. For more information on how Velocity Global makes opportunity borderless for people everywhere, visit www.velocityglobal.com. About Velocity Global Velocity Global gives you the power to build your team everywhere—combining seamless technology and local expertise in 185+ countries. We make it simple to compliantly hire, pay, and manage talent anywhere. With Velocity Global, the world is yours. Start hiring across borders at VelocityGlobal.com. Contact Details Media Contact press@velocityglobal.com Company Website https://velocityglobal.com/

September 19, 2023 08:00 AM Mountain Daylight Time

Image

First Human Clinical Trials Of A Potentially “Game-Changing Broad Spectrum Antiviral” Are Progressing Successfully – Drug Could Treat COVID, RSV And Many Other Respiratory Viruses

Benzinga

By Rachael Green, Benzinga As COVID cases begin to rise again, heralding the beginning of another COVID wave, new variants have appeared leading this wave. EG.5 (“Eris”) is currently in the majority in the U.S.A, but a very different variant, BA.2.86 (“Pirola”) is already rising in the number of cases. BA.2.86 carries more than 30 changes in its spike protein, as well as changes in other proteins. Scientists believe it is questionable whether the newest booster vaccine shots would be effective for this one. The newest vaccines are “single-agent” targeting the XBB variant. It is not known how effective the approved drugs (mainly Paxlovid - Pfizer Inc. (NYSE: PFE)) would be against this new variant, and further on, as the virus keeps changing. It is now clear that the SARS-CoV-2 virus is here to stay, and that it will keep changing as it continues to learn to avoid vaccines and antibodies and our own immune systems and continues to learn to resist existing old-fashioned drugs. Even without new variants, for clinically vulnerable patients COVID has always continued to be a terrifying reality. In light of this, the broad-spectrum antiviral that is based on a novel nanomedicines platform being developed by one emerging drug company could be promising. NanoViricides, Inc (NYSE American: NNVC ) announced that it has made progress on its Phase 1a/1b clinical trial of NV-CoV-2, a novel antiviral drug candidate that has the potential to treat all strains of the coronavirus. The clinical-stage biotech reported that the safety and tolerability parts of the trial testing the antiviral in healthy subjects is nearly complete and it’s now preparing for the efficacy and dose optimization part of the trial with COVID patients. NanoViricides Broad Spectrum Antiviral Could Change How We Treat Viral Infections So far, NanoViricides has built a robust foundation of promising preclinical research that demonstrates the unique antiviral platform’s potential to treat not just COVID-19 but a wide range of other common and hard-to-treat viral diseases like other coronaviruses, RSV, shingles, herpes, rabies and the flu. The reason it could have such broad applicability is because the NanoViricides platform was specifically designed to target a particular binding site that’s common across many viruses and doesn’t change even as a virus mutates. Essentially, the nanoviricide platform mimics the binding site on a human cell that a virus would normally target in order to infect that cell. Then it seeks out the virus and when the virus binds to the nanoviricide instead, the drug candidate immediately engulfs the virus, where it’s unable to infect the patient’s cells or reproduce. The First Of These Drugs Is Now In Human Phase 1a And 1b Clinical Trials The Phase 1a/1b clinical trial includes single-ascending dose (SAD) and multiple-ascending dose (MAD) safety and tolerability studies in healthy subjects. NanoViricides reported that 26 of the 36 volunteers in the SAD study and 17 of the 36 volunteers in the MAD study have already completed the program. And so far, the early data looks promising. Neither adverse events nor serious adverse events have been found to date in either study. "The excellent safety and tolerability of NV-CoV-2 in both formulations in the clinical trials is consistent with the results of pre-clinical animal studies, giving us confidence that our preclinical animal studies can be expected to be predictive of human clinical trials,” said NanoViricides Executive Chairman and President, Anil R. Diwan, Ph.D. Ongoing Phase 1a And 1b Clinical Trials Will Give First Indication Of Nanoviricides Efficacy In Humans With that baseline of safety and tolerability, the next part of the trial is to enroll COVID patients in the trial and start evaluating whether the positive preclinical effectiveness results for the drug will translate to human trials. Once this trial is finished, NanoViricides plans to seek permission to move into phase 2 clinical trials from multiple regulatory agencies worldwide. Of note, the same drug was found to be effective in pre-clinical studies against another important respiratory virus, RSV. Such a broad spectrum antiviral effectiveness is reminiscent of the development of antibiotics against bacteria. This could be a game-changing development in antiviral therapeutics. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 19, 2023 09:25 AM Eastern Daylight Time

AmeriLife Wealth Announces New Distribution Growth and Wealth Transformation Division

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, today announced the formation of Distribution Growth and Wealth Transformation, a newly created division within AmeriLife Wealth designed to support business development and organic growth, and accelerate the integration of its network of leading distribution companies and wealth advisory firms. “As we break through traditional distribution models and provide holistic solutions to the market we serve, it’s critical that we focus the right talent and resources to help us fundamentally transform the way in which we deliver value,” said Mike Vietri, Chief Distribution Officer of AmeriLife Wealth. “This team will spearhead our strategic focus and enhance our Wealth Distribution Platform, while also capitalizing on selling synergies and opportunities to leverage best-in-class solutions across our platform, better supporting those we serve.” Andrew “Andy” Sheen, most recently senior vice president and head of AmeriLife’s BizRev Group (BRG), will lead the Distribution Growth and Wealth Transformation team, reporting to Vietri. In this newly created role, Sheen will also leverage his considerable industry experience to lead all efforts surrounding AmeriLife Wealth’s market positioning while collaborating with AmeriLife Wealth leaders to deliver best practices, business development strategies, and sales and resource synergies. Sheen joined AmeriLife in December 2020 from Saybrus Partners, where he oversaw product development for the company’s annuity and life distribution. Prior to Saybrus, from 2009 to 2012, Sheen served his first stint with AmeriLife as its director of Financial Services, managing annuity and life product development for the company with its carrier partners. He began his career at CDA of America in various, and increasingly senior, product development, sales, and marketing roles. “I’m thankful to Mike for this opportunity and excited to bring my nearly 20 years of experience on the both carrier and distribution side to this new endeavor,” said Sheen. “‘Growth’ and ‘transformation’ are two sides of the same coin and essential to both accelerating the success of our affiliated partners, but also ensuring they remain one step ahead of consumer demands and the constant changes in our industry.” AmeriLife Wealth Continues to Grow Its Leadership Ranks The establishment of the new division and Sheen’s elevation builds upon significant strategic changes to AmeriLife’s Distribution structure as well as leadership changes within both its Wealth and Health Distribution organizations. In addition to Sheen’s appointment, the following senior roles within AmeriLife Wealth were also announced: Kelly Atkinson has been named Senior Vice President of Distribution Operations and Chief of Staff for AmeriLife Wealth, an expansion of her current role with a strategic focus on supporting Wealth’s growing executive leadership team and priority initiatives. In this expanded role, Atkinson will also continue to support enterprise campaigns and initiatives that span AmeriLife’s Wealth and Health distribution organizations. With Atkinson’s elevation, Crystal Santillanes has assumed an expanded role as Vice President of Distribution Operations. With a focus on driving action and alignment with Distribution goals, Santillanes is accountable for overseeing a variety of enterprise-wide Distribution initiatives and campaigns, in partnership with various functional areas across the company. Santillanes and her team is also responsible for Distribution meetings, events, and incentive programs. Bob Yates has been named Vice President, Distribution Business Analytics. In his new role, Yates will focus on partnering with Wealth and Health Distribution leadership and AmeriLife’s affiliates to maximize the value of available data, providing financial and market analysis, interpreting production results, and forecasting and developing business trend insights to support data-driven strategic planning, business development, and decision making. Yates will continue to collaborate with AmeriLife’s Enterprise Data and Analytics (EDA) team to support enterprise level data collection and reporting as well as ad hoc Distribution analysis needs. Lastly, Christy Appleang, CPA, joins the organization as Vice President, Financial Operations, responsible for leading all budgeting processes as well as developing strategic budgetary policies and guidelines to help meet short and long-term financial goals. Appleang brings 20 years of financial planning and analysis experience to AmeriLife Wealth, most recently serving as Senior Director of Finance for national grocer, Kroger, in its Health & Wellness Specialty Pharmacy Retail Division. Prior to Kroger, she served as Chief Financial Officer for Northwestern Mutual’s Southeast region. “We’re incredibly grateful for Andy’s, Kelly’s, Crystal’s and Bob’s continued dedication to our business, and are excited to welcome Christy to our team, as we continue our mission of transforming Wealth distribution for our affiliated agents and advisors,” added Vietri. “The growth of our team is a testament to what we’re building here at AmeriLife, and I look forward to working with each of them in their new roles.” ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

September 19, 2023 09:00 AM Eastern Daylight Time

Discern Security lands funding round as it launches world's first AI powered security policy management platform

Discern Security

In an era where global organizations collectively invested over $150 billion in cybersecurity measures last year*, the escalating proliferation of cyberattacks resulting in trillions of dollars in annual damages, underscores the critical need for cybersecurity innovation. Addressing this existential threat, Discern Security, the pioneering AI-driven policy management cybersecurity startup, has emerged from stealth with a $3m seed funding round. The funding round was led by a diverse investor consortium including BoldCap, WestWave Capital, Cyber Mentor Fund, Security Syndicate, along with influential Global Chief Information Security Officers (CISOs). This spread of investors underscores the opportunity Discern Security presents for the cybersecurity community. Established in 2023 by seasoned entrepreneurs Sai Venkataraman, Santhosh Purathepparmbil, and Rohan Puri, Discern Security aspires to reshape the cybersecurity landscape by harnessing the formidable power of AI. The company functions as a "Policy Intelligence Hub," leveraging AI capabilities to monitor and optimize security controls across a multitude of cybersecurity tools for its clients. This innovative approach fosters the development of a cohesive cybersecurity mesh architecture, facilitating seamless integration among various security products. Discern Security addresses three pivotal challenges confronting the industry. Firstly, it empowers organizations to maximize the efficacy of their security investments by enhancing the performance of existing products. Secondly, it alleviates the industry-wide shortage of cybersecurity expertise by taking on the operational heavy lifting, enabling teams to focus on strategic initiatives. Lastly, it tackles the inherent issue of standalone security products by simplifying the complex configuration process, thereby enhancing both security and productivity. Through its Policy Intelligence Hub, Discern Security empowers organizations to visualize and optimize their security configurations, ensuring continuous dynamic policy management throughout their cybersecurity tool arsenal. In stark contrast to conventional static and compartmentalized security solutions, Discern Security's platform adopts a proactive, interconnected approach to cybersecurity. By incorporating AI into the equation, the platform enables businesses to manage their security resources with greater efficiency while fortifying defenses against advanced cyber threats. Sai Venkataraman, Co-founder and CEO at Discern Security, commented: "The cybersecurity landscape demands perpetual innovation and fine-tuning, and our team at Discern Security is resolutely committed to ushering in a paradigm shift. With our platform, businesses gain the advantage of a comprehensive security strategy that not only mitigates risks but also optimizes their security investments. Our mission is to deliver world-class cybersecurity solutions transcending geographical boundaries, safeguarding organizations worldwide." Discern Security's solution has already gained significant traction, forging partnerships with numerous Fortune 500 corporations and top-tier cybersecurity firms. The proceeds from this funding round will be allocated to expand the product offering, incorporating essential integrations, and continuing the recruitment of a global team of cybersecurity experts. Discern Security is poised to extend these solutions to businesses worldwide, actively safeguarding their digital assets against evolving cyber threats. Sathya Nellore Sampat, General Partner at BoldCap, remarked, "Security threats to organizations continually evolve, yet security policies and configurations at most organizations are infrequently updated, often once or twice a year. This leads to increased risk and vulnerability. Discern's AI-powered solution strategically addresses this need and is poised to create a new category and become a market leader in this space. We are delighted to lead their funding round." Warren Weiss, Managing General Partner at WestWave Capital, added, "Discern Security's innovative AI-driven approach to cybersecurity promises to make a significant impact in the industry. We believe that Sai, Santhosh, and Rohan's visionary leadership positions them as category creators, and we eagerly anticipate supporting their mission to fortify businesses against ever-evolving cyber threats." About Discern Security Discern Security is the world's first AI-Driven cybersecurity startup founded by repeat entrepreneurs Sai Venkataraman, Santhosh Purathepparmbil, and Rohan Puri. The company is on a mission to revolutionize cybersecurity by leveraging the power of AI to create a dynamic, interconnected platform for security configuration and policy management. With a team spread across US and India, Discern Security aims to become a global leader in cybersecurity solutions, safeguarding businesses from the ever-evolving cyber threats. About BoldCap BoldCap helps Bold founders from day zero. BoldCap invests 500K-1M at the seed stage and specializes in helping founders build out their GTM. About WestWave Capital Deep-Tech takes deep partnerships. Founded by former entrepreneurs, WestWave knows that founders need more than just capital. WestWave Capital invests in market defining pre-seed, seed and series A enterprise start ups. Contact Details Discern Security Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.discernsecurity.com/

September 19, 2023 09:00 AM Eastern Daylight Time

Image

B2B Video Visibility & Monetization Platform VideoXRM’s Beta Launch Surpasses 5,000 Video Uploads; Expands Content Sourcing and Audience Engagement with Launch of “Company Advocate”

VideoXRM

VideoXRM, the pioneering B2B video platform that utilizes precise subject indexing and granular search capabilities to drive greater return on investment from video assets, announced today that its Beta launch has surpassed 5,000 video uploads to its platform from a growing base of companies. VideoXRM also announced the launch of its “Company Advocate” functionality to accelerate the growth of its video library through expanded audience engagement. There is no cost to upload or search for content on VideoXRM. The VideoXRM platform provides 75 search parameters including 25 different video/audio characteristics to identify and index the unique attributes of each video, including subject, industry, specialty, participants, roles, geography, corporate status, management, etc. “Company Advocate” VideoXRM’s new “Company Advocate” functionality enables business content creators, customers, partners, media outlets or fans to upload content on behalf of a company. This new feature is designed to expand the reach, engagement, and growth of content on the VideoXRM platform. David Baker, VideoXRM’s Founder and CEO, commented, “We are excited by the growing engagement and constructive customer comments and suggestions we have gained through our Beta launch. This feedback loop has already contributed to new features such as the ‘Company Advocate’ functionality that substantially expands potential content sources and value for our platform.” VideoXRM brings the “X factor” to Customer Relationship Management (CRM) by expanding it ALL stakeholders including partners, constituents, employees, analysts, suppliers, researchers, recruiters, marketers, journalists, investors, citizens, bankers, etc. Given the growing user preference for video and rich media, VideoXRM provides a powerful new medium for exposure and precise searches. About VideoXRM ( VideoXRM.com ) VideoXRM is a global, searchable video and audio sharing and networking platform connecting corporate rich media content with all potential stakeholders. The platform and smart search technology creates value and knowledge from mountains of unstructured digital media, delivering greater ROI from content investments. VideoXRMâs mission is harnessing the enhanced communicative power of rich media through a new distribution and discovery paradigm. VideoXRM was Co-founded by David N. Baker, who formed Revere Data LLC (Sectorbase) which was acquired by FactSet Data Systems, Inc. His Co-founders are Vadim A. Tarasov, Byron Kwok, and David Guzy. Connect with us on LinkedIn and Twitter and Facebook. Contact Details Catalyst IR David C. Collins +1 212-924-9800 videoxrm@catalyst-ir.com Company Website https://videoxrm.com

September 19, 2023 08:55 AM Eastern Daylight Time

Trust & Will Proudly Achieves B Corporation Certification

Trust & Will

Trust & Will, the leading digital estate planning and settlement platform, is proud to announce its official certification as a B Corporation. With a mission to help every family leave a legacy, this recognition highlights Trust & Will's commitment to sustainability, social responsibility, and ethical business practices. Trust & Will joins the global movement that business can be a force for good led by B Lab, a nonprofit network aimed to reshape the incentives around doing business—prioritizing people, communities, and the planet in addition to profit. “Six years ago, we set out on a mission to make estate planning affordable and accessible to every family in order to create legacies that span multiple generations,” said Cody Barbo, CEO and Founder of Trust & Will. “Becoming a B Corp was a conscious decision and massive undertaking to ensure that we also leave this world a better place than we found it and hold ourselves accountable to the highest standards of ethics, governance, and responsibility.” Based on the B Impact Assessment, Trust & Will earned an overall score of 97.7, outperforming the required score of 80. The company was also recently named to Inc.’s list of “The 5,000 Fastest Growing Companies in America,” and routinely is recognized as an Inc. Best Workplace. Trust & Will joins the ranks of businesses, such as Patagonia, Ben & Jerry’s, and Athleta, that are using their influence to create a positive impact beyond financial gains. B Corps are a global community of companies that meet the highest standards of verified social and environmental performance, public transparency, and legal accountability to balance profit and purpose. ABOUT TRUST & WILL Trust & Will is simplifying estate planning and settlement with attorney-approved, legally valid documents and processes designed to adhere to individual state guidelines. Since 2017, we’ve helped hundreds of thousands of Trust & Will members leave their legacy with an affordable way to create an estate plan or settle the estate of a loved one. Our platform uses bank-level encryption that protects customer data and complies with the highest security standards, including SOC 2 and HIPAA. Trust & Will is a certified B Corporation and is the official estate planning benefit provider for AARP members, along with several leading financial institutions, who all believe in our mission of helping every family leave their legacy. Contact Details Trust & Will Danielle Nuzzo +1 631-807-7772 danielle@trustandwill.com Company Website https://trustandwill.com

September 19, 2023 07:01 AM Eastern Daylight Time

SMX® Commits to Advancing Contract Management Excellence with Adoption of NCMA Contract Management Standard

National Contract Management Association

SMX®, a trusted contractor in advanced technology solutions, proudly announces its adoption of the National Contract Management Association's (NCMA) Contract Management Standard (CMS™). This strategic move underscores SMX's unwavering dedication to fostering profession-wide best practices, contracting principles, terminology, processes, and cultivating professional career development within the field. The NCMA Contract Management Standard serves as a global language for contract management professionals across various industries and organizations. It provides thought-leading organizations, like SMX, a unified framework to articulate and discuss contract management phases, domains, competencies, and skills. As SMX incorporates the CMS as a cornerstone of its corporate Quality Management System, customers can expect enhanced contract management services, increased operational efficiency, and a more transparent and streamlined experience throughout their contract lifecycle. "SMX takes immense pride in being an early adopter of CMS, a testament to our commitment to delivering unparalleled service to both our internal stakeholders and valued clients," remarked Rick Schutz, Vice President, Corporate Counsel at SMX. "This adoption reflects our pursuit of excellence in every facet of contract management." Kraig Conrad, Chief Executive Officer of NCMA, emphasized, “the SMX adoption of the CMS™ embodies our unwavering pursuit of a common language for contract management across organizations and around the world.” With the integration of the CMS into the frameworks of Federal Acquisition Certification in Contracting (FAC-C) and the Department of Defense framework (DAWIA), SMX's embrace of the NCMA CMS aligns seamlessly with the evolving landscape of contract management. As SMX embarks on this transformative journey, they look forward to not only exceeding their customers' expectations but also contributing to the evolution and standardization of contract management practices worldwide. For more information on NCMA's Common Language Adoption, please visit: www.ncmahq.org/adopters The National Contract Management Association (NCMA) – www.ncmahq.org – stands as the premier contract management organization whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. About SMX SMX is a leader in next-generation mission support, digital transformation and IT solutions operating in close proximity to clients across the U.S. and around the globe. SMX delivers scalable and secure solutions combined with the mission expertise needed to accelerate outcomes for the Department of Defense, Intelligence Community, Public Sector, Fortune 1000, and other public and private sector clients. For more information on our solutions, please visit https://www.smxtech.com/. Contact Details NCMA Holly DeHesa +1 281-865-3296 holly.dehesa@ncmahq.org Company Website https://www.ncmahq.org/

September 19, 2023 06:00 AM Eastern Daylight Time

Wishpond to Participate in Upcoming Maxim Group and LD Micro Investor Conferences

Wishpond Technologies Ltd.

Wishpond Technologies Ltd. (TSXV: WISH, OTCQX: WPNDF) (the “ Company ” or “ Wishpond ”), a provider of marketing-focused online business solutions, is pleased to announce that Ali Tajskandar, Chairman and CEO of Wishpond, will be participating in the following upcoming investor conferences: Maxim Group 2023 Virtual Tech Conference Series: Emerging Growth in A.I. Presentation Date: Wednesday, September 27, 2023 Time: 3:00 PM PT – Track #2 Link: https://m-vest.com/events/virtual-tech-ai-09262023 The continuous evolution of AI is paving the way for groundbreaking applications in the technology sector. In the first installment of the 2023 Virtual Tech Conference, Maxim Group dives deep into how companies are leveraging AI and computer vision to unlock new opportunities, spanning from semiconductor innovations to fintech breakthroughs. Maxim Senior Analysts will facilitate engaging dialogues with CEOs and key management of emerging growth companies with a strong focus on AI. LD Micro Main Event XVI Presentation Date: Wednesday, October 4, 2023 Presentation Time: 9:00 AM PT – Track #3 Register to watch the virtual presentation here: https://me23.sequireevents.com/. Mr. Ali Tajskandar will be presenting at the 16th annual LD Micro Main Event taking place at the Luxe Sunset Boulevard Hotel in Los Angeles from October 3-5th. Mr. Tajskandar will be providing a live presentation on Wednesday, October 4 th, 2023 at 9:00 am PT (12:00 pm ET), and will be conducting in-person 1on1 meetings at the conference venue. For more info, please visit https://ldmicro.com. Wishpond Technologies Ltd. “Ali Tajskandar” Chairman and Chief Executive Officer About Wishpond Technologies Ltd. Based out of Vancouver, British Columbia, Wishpond is a provider of marketing-focused online business solutions. Wishpond is a leading provider of digital marketing solutions that empower entrepreneurs to achieve success online. The Company’s Propel IQ platform offers an “all-in-one” marketing suite that provides companies with marketing, promotion, lead generation, ad management, referral marketing, sales conversion and outbound sales automation capabilities on one integrated platform. Wishpond replaces disparate marketing solutions with an easy-to-use product, for a fraction of the cost. Wishpond serves over 4,000 customers who are primarily small and medium-sized businesses (SMBs) in a wide variety of industries. The Company has developed cutting-edge marketing technology solutions including an artificial intelligence (AI) powered website builder and continues to add new features and applications. The Company employs a Software-as-a-Service (SaaS) business model where most of the Company’s revenue is subscription-based recurring revenue which provides excellent revenue predictability and cash flow visibility. Wishpond is listed on the TSX Venture Exchange under the ticker “WISH”, and on the OTCQX Best Market under the ticker “WPNDF”. For further information, visit: www.wishpond.com. Contact Details Pardeep S. Sangha Investor Relations, Wishpond Technologies Ltd. +1 604-572-6392 investor@wishpond.com

September 19, 2023 06:00 AM Eastern Daylight Time

1 ... 175 176 177 178 179 ... 589